17430-71-6Relevant articles and documents
Barker
, p. 1670 (1960)
Oxygenated hydrocarbon ionic surfactants exhibit CO2 solubility
Fan, Xin,Potluri, Vijay K.,McLeod, M. Chandler,Wang, Yang,Liu, Juncheng,Enick, Robert M.,Hamilton, Andrew D.,Roberts, Christopher B.,Johnson, J. Karl,Beckman, Eric J.
, p. 11754 - 11762 (2005)
Several oxygenated hydrocarbons, including acetylated sugars, poly(propylene glycol), and oligo-(vinyl acetate), have been used to generate CO2-soluble ionic surfactants. Surfactants with vinyl acetate tails yielded the most promising results, exhibiting levels of CO2 solubility comparable to those associated with fluorinated ionic surfactants. For example, a sodium sulfate with single, oligomeric vinyl acetate (VAc) tails consisting of 10 VAc repeat units was 7 wt % soluble in CO2 at 25 °C and 48 MPa. Upon introduction of water to these systems, only surfactants with the oligomeric vinyl acetate tails exhibited spectroscopic evidence of a polar environment that was capable of solubilizing the methyl orange into the CO2-rich phase. For example, a single-phase solution of CO 2, 0.15 wt % sodium bis(vinyl acetate)8 sulfosuccinate, and water, at water loading (W) values ranging from 10 to 40 at 25 °C and 34.5 MPa, exhibited a methyl orange peak at 423 nm. This result indicated that the core of a reverse micelle provided a microenvironment with a polarity similar to that of methanol. Quantum chemical calculations indicate that the acetylated sugars may be too hydrophilic to readily form reverse micelles, whereas the VAc-based surfactants appear to have the correct balance of hydrophilic and hydrophobic forces necessary to form reverse micelles.
COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
-
Page/Page column 242, (2010/08/04)
The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract
